TargetMol
Abiraterone Acetate (CB7630) is an androstene derivative that inhibits STEROID 17-ALPHA-HYDROXYLASE and is used as an ANTINEOPLASTIC AGENT in the treatment of metastatic castration-resistant PROSTATE CANCER.
More Information
Supplier Page
TargetMol
Abiraterone (CB-7598) is an effective steroidal cytochrome P450 17alpha-hydroxylase-17, 20-lyase (CYP17) inhibitor (IC50: 4 nM).
More Information
Supplier Page
TargetMol
Abiraterone (CB-7598) is an effective steroidal cytochrome P450 17alpha-hydroxylase-17, 20-lyase (CYP17) inhibitor (IC50: 4 nM).
More Information
Supplier Page
LFM-A13
10 mg
| 99.90%
TargetMol
LFM-A13(IC50=2.5 μM), a specific Bruton’s tyrosine kinase (BTK), is more than 100-fold specificity than other protein kinases, such as JAK1, JAK2, HCK, EGFR, and IRK.
More Information
Supplier Page
LFM-A13
25 mg
| 99.90%
TargetMol
LFM-A13(IC50=2.5 μM), a specific Bruton’s tyrosine kinase (BTK), is more than 100-fold specificity than other protein kinases, such as JAK1, JAK2, HCK, EGFR, and IRK.
More Information
Supplier Page
LFM-A13
50 mg
| 99.90%
TargetMol
LFM-A13(IC50=2.5 μM), a specific Bruton’s tyrosine kinase (BTK), is more than 100-fold specificity than other protein kinases, such as JAK1, JAK2, HCK, EGFR, and IRK.
More Information
Supplier Page
TargetMol
LFM-A13(IC50=2.5 μM), a specific Bruton’s tyrosine kinase (BTK), is more than 100-fold specificity than other protein kinases, such as JAK1, JAK2, HCK, EGFR, and IRK.
More Information
Supplier Page
TargetMol
CP-466722, an effective and reversible ATM inhibitor, does not inhibit ATR and PI3K or PIKK family members in cells.
More Information
Supplier Page
TargetMol
CP-466722, an effective and reversible ATM inhibitor, does not inhibit ATR and PI3K or PIKK family members in cells.
More Information
Supplier Page
TargetMol
CP-466722, an effective and reversible ATM inhibitor, does not inhibit ATR and PI3K or PIKK family members in cells.
More Information
Supplier Page